[144] GRAIL, Inc. SEC Filing
A Form 144 notice was filed by Aaron Freidin of GRAIL, Inc. (GRAL) proposing to sell 79,460 shares of common stock acquired through restricted stock unit vesting on April 3, 2026. The filing also details previous sales by Mr. Freidin in March 2026 totaling 12,720 shares. This is considered a routine insider liquidity filing, with a modest magnitude relative to larger institutional transactions.
[144] GRAIL, Inc. SEC Filing
GRAIL, Inc. has filed a Form 144 detailing Rule 144 transactions involving its Common Stock. The filing reports 106,970 shares acquired upon vesting of restricted stock units on April 3, 2026, and three sales by Joshua J. Ofman in early March 2026. The Securities Compliance Analyst notes this as a routine Rule 144 notice, indicating no clear material change to the capital structure.
Is GRAIL (GRAL) Turning Superpower Partnership Into a Scalable Edge in Preventative Oncology?
GRAIL, Inc. has partnered with Superpower to integrate its Galleri multi-cancer early detection blood test into Superpower's preventative health platform. This collaboration aims to position Galleri as part of a comprehensive early warning system, broadening its access and usage. While the partnership enhances distribution, GRAIL's core investment narrative still hinges on potential FDA approval and achieving profitability, with analysts maintaining high price targets based on long-term screening potential.
Price-Driven Insight from (GRAL) for Rule-Based Strategy
This article provides price-driven insights for Grail Inc Com (NASDAQ: GRAL) based on AI models, supporting an overweight bias despite identifying no clear price positioning signal and elevated downside risk. It details three institutional trading strategies: a Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Strategy, along with a multi-timeframe signal analysis. The analysis highlights strong sentiment across all horizons and provides specific support and resistance levels for near, mid, and long-term periods.
GRAL Investors Invited to Join Fraud Investigation
The Schall Law Firm has initiated an investigation into GRAIL, Inc. (NASDAQ: GRAL) following the company's announcement of disappointing results from its NHS-Galleri trial on February 19, 2026, which led to a sharp drop in stock price. The investigation will determine if GRAIL made false or misleading statements and failed to disclose crucial information to investors. Investors who have suffered losses are encouraged to join the investigation and potentially participate in a class-action lawsuit.
GRAL Investors Have Opportunity to Join GRAIL, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm is investigating potential securities law violations by GRAIL, Inc. (NASDAQ: GRAL) following a sharp drop in share price. This investigation comes after GRAIL announced on February 19, 2026, that its NHS-Galleri trial did not meet its primary endpoint of statistically significant Stage III-IV reduction. Shareholders who suffered losses are encouraged to contact the firm for a free consultation regarding their rights.
GRAL SEC Filings - Grail Inc 10-K, 10-Q, 8-K Forms
This page provides access to Grail Inc.'s (GRAL) SEC filings, including annual 10-K, quarterly 10-Q, material event 8-K reports, and insider trading forms. It highlights recent 8-K filings detailing private placements, collaboration agreements with Samsung, and an equity distribution agreement. The platform also offers AI-powered summaries for easier understanding of these regulatory documents.
Grail partnering with Superpower to offer Galleri cancer early detection test
Grail has announced a partnership with Superpower to offer its Galleri multi-cancer early detection test. This collaboration aims to make the innovative Galleri test more widely accessible. Superpower will facilitate the offering of Grail's test, which detects over 50 types of cancer, to a broader population.
Superpower partners with GRAIL to offer multi-cancer blood test
Superpower has partnered with GRAIL, Inc. to provide its members access to the Galleri multi-cancer early detection test. This blood-based test screens for over 50 cancer types, and its integration into Superpower's health platform aims to transform cancer screening and proactive health management. Despite GRAIL being unprofitable due to investment in technology, analysts remain optimistic about the multi-cancer early detection market's potential.
GRAIL (Nasdaq:GRAL) - Stock Analysis
This report provides a stock analysis for GRAIL (Nasdaq:GRAL), a commercial-stage healthcare company specializing in multi-cancer early detection. It details the company's financial performance, future growth prospects, risks, and recent news, indicating a current valuation as undervalued by analysts. Key highlights include growth forecast, volatile share price, and significant insider selling, alongside positive clinical results and regulatory progress for its Galleri test.
UBS (AMUB) offers 15.30% autocallable notes linked to GRAIL (GRAL)
UBS AG is offering Trigger Autocallable Yield Notes linked to GRAIL, Inc. common stock, totaling $575,000, with a 15.30% annual coupon and maturing on March 30, 2029. These notes provide quarterly payments unless automatically called, but investors face principal loss if GRAIL's stock falls below a 50% downside threshold at maturity and the notes haven't been called. The estimated initial value of each note is below the issue price, and all payments are subject to UBS's creditworthiness.
GRAIL, Inc. Stock Hits Day Low of $47.55 Amid Price Pressure
GRAIL, Inc. (a small-cap pharmaceuticals & biotechnology company) saw its stock price drop by 7.04% to an intraday low of $47.55. Despite this recent decline, the company has shown a 69.66% return over the past year, outperforming the S&P 500. Institutional holdings remain strong at 93.34%, and raw material costs have decreased by 37.9% year-over-year.
JPMorgan Chase & Co. Raises Stake in GRAIL, Inc. $GRAL
JPMorgan Chase & Co. increased its holdings in GRAIL, Inc. (NASDAQ:GRAL) by 159.1% in the third quarter, bringing its total ownership to 206,120 shares valued at approximately $12.19 million. Despite insider selling by CFO Aaron Freidin and President Joshua Ofman, GRAIL reported better-than-expected Q3 EPS of -$2.44, beating estimates, and generated $43.6 million in revenue, though it remains unprofitable. Analysts hold a "Moderate Buy" consensus rating with an average target price of $82.00, reflecting mixed views on the biotechnology company focused on early cancer detection.
Vanguard disaggregates holdings; GRAIL now shows 0% ownership (GRAL)
The Vanguard Group filed an amended Schedule 13G/A, reporting 0% beneficial ownership of GRAIL Inc (GRAL) common stock. This change is due to an internal realignment on January 12, 2026, which causes certain Vanguard subsidiaries and business divisions to report their beneficial ownership separately, as per SEC Release No. 34-39538. This is an administrative disclosure and does not indicate a sale of shares by Vanguard, but rather a change in reporting structure.
Levi & Korsinsky, LLP: Grail (GRAL) Guided to 2030 Cash Runway While Key Trial Risk Went Unaddressed
Levi & Korsinsky, LLP is investigating Grail, Inc. (NASDAQ: GRAL) after the company's stock lost approximately 50% following the failure of the NHS Galleri randomized trial to meet its primary endpoint. The investigation centers on whether Grail's forward guidance, which projected a cash runway into 2030 and a specific burn rate, omitted critical risks related to the trial outcome. Shareholders who suffered losses are encouraged to contact the firm regarding their legal rights.
Levi & Korsinsky, LLP: Grail (GRAL) Guided to 2030 Cash Runway While Key Trial Risk Went Unaddressed
Levi & Korsinsky, LLP is investigating Grail, Inc. (GRAL) after its stock fell by 50% following the failure of the NHS Galleri trial to meet its primary endpoint. The investigation focuses on whether Grail's management omitted material headwinds regarding the trial's risk in their forward guidance, which projected a cash runway into 2030 based on the success of these milestones. Shareholders who suffered losses are encouraged to contact the firm.
Illumina Inc. stock navigates Grail divestiture challenges amid biotech sector pressures
Illumina Inc. (ISIN: US4523271090) is facing market pressures due to its ongoing Grail divestiture and broader biotech sector headwinds, including regulatory scrutiny and softening demand. The company's stock performance is largely affected by the $8 billion Grail acquisition's legal battles and its subsequent spin-off plans, which aim to resolve antitrust concerns while refocusing on core sequencing platforms. US investors are closely watching the divestiture's execution risks, Grail's path to commercialization, and the overall biotech market recovery for potential investment opportunities.
Illumina Inc stock faces headwinds amid Grail divestiture and biotech sector pressures
Illumina Inc. is facing significant challenges due to the divestiture of its Grail subsidiary, regulatory pressures from the FTC and European authorities, and increasing competition in its core genomic sequencing business. The successful separation of Grail, coupled with new product launches and strategic initiatives in multi-omics integration, will be crucial for the company to regain investor confidence and reaccelerate growth. Despite these headwinds, analysts suggest the stock might be undervalued relative to peers, presenting a potential opportunity for US investors.
Illumina Inc. stock faces headwinds amid Grail divestiture scrutiny and biotech sector slowdown
Illumina Inc. (ISIN: US4523271090) is experiencing stock pressure due to the lasting impact of its Grail acquisition reversal and decreased demand in genomic sequencing. The company faces ongoing regulatory scrutiny, competitive pressures, and softening sales, despite having a robust balance sheet and investing heavily in R&D. While Illumina plans to focus on clinical genomics and strategic partnerships, US investors must carefully weigh the risks, including potential regulatory fines, competitive pricing wars, and macroeconomic factors, against its market dominance and innovative efforts.
(GRAL) Price Dynamics and Execution-Aware Positioning
This article analyzes Grail Inc Com (NASDAQ: GRAL) stock price dynamics, highlighting positive near-term sentiment while noting a weak mid-term bias within a long-term strength context. It details AI-generated trading strategies for different risk profiles, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis indicating support and resistance levels. The report also mentions elevated downside risk due to a lack of additional long-term support signals.
Illumina Inc. stock faces renewed scrutiny amid Grail divestiture delays and biotech sector headwind
Illumina Inc. is encountering renewed scrutiny due to persistent delays in its Grail divestiture and broader biotech sector headwinds. Regulatory hurdles, particularly in the EU and US, are extending the timeline for spinning off Grail, negatively impacting margins and investor confidence. Despite these challenges, the company is pivoting towards high-growth areas like spatial transcriptomics and AI-powered data analysis, which are seen as long-term catalysts by investors, especially in the DACH region.
Levi & Korsinsky, LLP: Grail (GRAL) Guided to 2030 Cash Runway While Key Trial Risk Went Unaddressed
Levi & Korsinsky, LLP is investigating Grail, Inc. (NASDAQ: GRAL) after the company's stock lost about 50% of its value following the failure of the NHS Galleri trial to meet its primary endpoint. The firm is examining whether Grail's forward guidance, which projected a cash runway into 2030 and significant clinical milestones, omitted material headwinds known to management regarding the trial's risk. Investors who suffered losses are encouraged to contact the law firm.
Grail upgraded to Buy from Hold at TD Cowen
TD Cowen upgraded Grail (GRAL) to Buy from Hold, setting a price target of $65. The firm believes the recent 60% selloff in shares, following the NHS-Galleri study results and a CEO change, presents an attractive entry point. Analysts are bullish on Grail's first-mover advantage in the multi-cancer early detection market, noting that key opinion leaders view the NHS study design as the reason for the miss and consider the 20% shift in stage IV cancer to be meaningful.
Grail stock jumps after TD Cowen upgrade on cancer test outlook
Grail Inc. (NASDAQ:GRAL) shares rose 6.2% after TD Cowen upgraded the stock to Buy, despite a recent setback in its NHS Galleri trial. Analyst Dan Brennan remains optimistic about the $70 billion multi-cancer early detection market, believing it will revolutionize cancer diagnosis. Key opinion leader feedback suggests potential FDA approval and a 50% chance of Medicare approval, contributing to a $65 price target.
LEVI & KORSINSKY, LLP: GRAIL (GRAL) GUIDED TO 2030 CASH RUNWAY WHILE KEY TRIAL RISK WENT UNADDRESSED
Levi & Korsinsky, LLP is investigating Grail, Inc. (NASDAQ: GRAL) after the company lost approximately 50% of its market value following the disclosure that its NHS Galleri randomized trial failed to meet its primary endpoint. The law firm is examining whether Grail's forward guidance, specifically its cash runway into 2030 and burn-rate guidance of $290 million for 2025, omitted material risks related to the trial's outcome, which were known to management. Shareholders who suffered losses are encouraged to contact the firm to discuss their legal rights.
TD Cowen upgrades Grail stock rating to buy on cancer detection market potential
TD Cowen upgraded GRAIL, Inc. (NASDAQ:GRAL) to Buy from Hold, citing the significant potential of the multi-cancer early detection market, despite lowering its price target to $65 from $114. The firm believes MCED testing will revolutionize cancer detection and anticipates FDA approval for GRAIL's technology, with a 50% probability of Medicare approval. This upgrade closely follows GRAIL's fourth-quarter earnings report, a miss in its NHS-Galleri study's primary endpoint, and a recent CEO leadership change.
GRAIL, Inc. (NASDAQ:GRAL) Sees Significant Increase in Short Interest
GRAIL, Inc. (NASDAQ:GRAL) experienced a substantial 15.3% increase in short interest in February, reaching over 6.29 million shares. Despite this, the company's shares rose 3.8% after reporting Q4 earnings that beat analyst estimates, although it remains unprofitable. Insider selling has been significant, while analysts maintain a "Hold" rating with an average target price of $90.17.
Does GRAIL (GRAL) Elevating Josh Ofman to CEO Reframe Its Management Quality Narrative?
GRAIL, Inc. is undergoing a leadership change, with President Josh Ofman set to replace retiring CEO Bob Ragusa on June 1, 2026. While this transition puts an experienced internal executive at the helm, it does not significantly alter the primary investment drivers or risks for GRAIL, which include the Galleri PMA review, reimbursement decisions, and the mixed results of the NHS Galleri trial. Investors are encouraged to assess how these factors, along with GRAIL's projected financial growth, align with their own expectations and the current investment narrative.
Does GRAIL (GRAL) Elevating Josh Ofman to CEO Reframe Its Management Quality Narrative?
GRAIL announced that Josh Ofman will succeed Bob Ragusa as CEO on June 1, 2026, positioning an internal executive with extensive experience at the helm. This leadership change occurs as GRAIL faces challenges with its Galleri multi-cancer early detection test, including mixed results from the NHS Galleri trial, which did not meet its primary endpoint. The article explores how this transition, alongside trial outcomes, might influence GRAIL's investment narrative and risk profile, particularly regarding regulatory approval and reimbursement decisions, and underscores the need for investors to assess these factors against current financial forecasts.
Grail CEO Bob Ragusa to retire
Grail CEO Bob Ragusa will retire on June 1, 2026, and will be succeeded by Josh Ofman, the company's current president. This leadership change comes weeks after Grail's multi-cancer early detection test failed to meet its primary endpoint in a clinical trial. However, Guggenheim Securities analysts suggest the CEO transition was planned and not directly related to the trial results, which the company still plans to present at ASCO.
Farallon Capital Management LLC Buys 847,000 Shares of GRAIL, Inc. $GRAL
Farallon Capital Management LLC significantly increased its stake in GRAIL, Inc. (NASDAQ:GRAL) during Q3, purchasing an additional 847,000 shares to own 1,349,000 shares valued at $79.77 million. Other institutional investors also adjusted their holdings in GRAIL, while company insiders, including the CFO and CEO, sold shares in early March. GRAIL recently reported stronger-than-expected Q4 earnings and revenue, but analysts maintain a "Hold" rating with an average target price of $90.17.
GRAIL, Inc. (NASDAQ:GRAL) Receives Consensus Recommendation of "Hold" from Analysts
GRAIL, Inc. (NASDAQ:GRAL) has received a consensus "Hold" recommendation from six analysts, with an average target price of $90.17. The biotechnology company, focused on early cancer detection, recently reported Q4 EPS of ($2.44), beating estimates, but shows large negative margins. Insider selling, including by the president and CFO, occurred in early March.
Grail CEO to retire after failed cancer detection trial - San Francisco Business Times
Grail's CEO is set to retire following a failed cancer detection trial, after the company has burned through over $10 billion. The San Francisco Business Times reported on this development, highlighting the challenges faced by the early cancer detection firm.
Cancer detection company GRAIL elevates Josh Ofman to lead multi-cancer efforts
GRAIL (Nasdaq: GRAL) announced that CEO Bob Ragusa will retire effective June 1, 2026, and President Josh Ofman, MD, MSHS, will succeed him, joining the Board immediately. Ragusa will remain on the Board until June 1, 2026, and serve as a senior advisor through March 2027 to ensure a smooth transition. The company highlighted Ofman's extensive background in clinical medicine, health policy, and leadership of the Galleri evidence program as crucial for advancing regulatory and commercial progress in multi-cancer early detection.
Levi & Korsinsky, LLP: Grail (GRAL) Guided to 2030 Cash Runway While Key Trial Risk Went Unaddressed
Levi & Korsinsky, LLP is investigating Grail, Inc. (NASDAQ: GRAL) after its stock fell approximately 50% following the failure of the NHS Galleri randomized trial to meet its primary endpoint. The investigation focuses on whether Grail's forward guidance, which projected a cash runway into 2030 and a specific burn rate, omitted material risks related to the trial's potential failure, which was crucial for their stated clinical and regulatory milestones. Shareholders who suffered losses are encouraged to contact the firm.
GRAIL Announces Retirement of CEO Bob Ragusa and Appointment of Josh Ofman, MD, MSHS, as Successor
GRAIL, Inc. has announced that CEO Bob Ragusa will retire on June 1, 2026, to be succeeded by current President, Josh Ofman, MD, MSHS. Ofman has also been appointed to GRAIL's Board of Directors. This leadership transition follows a comprehensive succession planning process, with Ragusa continuing in a senior advisory role until March 2027.
A Persistent Patient’s Story
Richard Porter recounts his personal struggle with a cancer diagnosis discovered through Grail's Galleri blood test, which detected cancer before symptoms appeared. Despite initial skepticism from doctors and protocols designed for later-stage cancers, his persistence led to treatment, and he critiques the healthcare system's slow adoption of new technologies. He argues that systemic incentives and protocols can hinder personalized care and innovative approaches, especially for early cancer detection.
GRAIL, Inc. Hits Day High with 12.18% Surge Amid Market Challenges
GRAIL, Inc. stock surged 12.18% to an intraday high of USD 58.22, showing resilience despite recent weekly and monthly declines. The company has outperformed the S&P 500 over the past year with a 32.44% return, driven by a 20.45% growth in net sales and reduced raw material costs. Institutional investors also demonstrate confidence, increasing their holdings by 6.57% in the last quarter.
POM Health Announces Agreement with GRAIL to Offer Its Galleri® MCED Test
POM Health Systems, a cancer screening service, announced an agreement with GRAIL, Inc. to offer its Galleri® multi-cancer early detection (MCED) test. The Galleri test will be a core component of POM's subscription cancer screening plans, which also include other advanced testing and oncologist consultation. This partnership aims to provide more comprehensive and proactive cancer screening options for individuals, especially those aged 50 or older with an elevated risk for cancer.
Levi & Korskinsky, LLP: Grail (GRAL) Guided to 2030 Cash Runway While Key Trial Risk Went Unaddressed
Levi & Korsinsky, LLP is investigating Grail, Inc. (NASDAQ: GRAL) after the company lost approximately 50% of its market value following the failure of the NHS Galleri randomized trial to meet its primary endpoint. The law firm alleges that Grail's forward guidance, which projected a cash runway into 2030 and a specific burn rate, omitted the material risk associated with the trial's outcome. Shareholders who suffered losses are encouraged to contact the firm.
Vanguard Group Inc. Trims Stock Position in GRAIL, Inc. $GRAL
Vanguard Group Inc. reduced its stake in GRAIL, Inc. by 4.5% in the third quarter of 2025, selling 85,366 shares and now owning 1,816,993 shares valued at approximately $107.44 million. This move comes amid significant insider selling by the CEO and President, and mixed analyst ratings ranging from "sell" to "buy" with an average "Hold" rating. While GRAIL beat quarterly EPS estimates, it remains unprofitable with a deeply negative net margin.
How Investors Are Reacting To GRAIL (GRAL) Mixed NHS-Galleri Trial Results And Ongoing Net Losses
GRAIL (GRAL) recently reported mixed results from its NHS-Galleri trial, which did not meet its primary endpoint but showed positive shifts towards earlier cancer detection. Despite a significant net loss of US$408.4 million in 2025 against US$147.2 million in revenue, the investment case for GRAIL heavily relies on clinical and regulatory catalysts like the NHS-Galleri readout and pending FDA approval. Investors are now evaluating how these results and the company's financial situation will impact its future growth and valuation.
GRAIL (NASDAQ:GRAL) CFO Aaron Freidin Sells 9,573 Shares
GRAIL (NASDAQ:GRAL) CFO Aaron Freidin sold 9,573 shares of the company's stock on March 2nd at an average price of $50.17, totaling $480,277. This sale reduced his stake by 3% to 309,622 shares. Despite the sale, GRAIL recently reported quarterly earnings that topped analyst estimates, though the company remains unprofitable.
GRAIL (GRAL) president gets RSU grant, sells shares for taxes
GRAIL, Inc. president Joshua J. Ofman received a grant of 84,540 restricted stock units (RSUs) and subsequently sold 17,002 shares to cover tax withholdings. The RSUs will vest in annual installments starting February 28, 2027. Following these transactions, Ofman directly owns 436,508 shares of common stock, with an adjustment made to include 152 dividend shares from the GRAIL spin-off from Illumina.
GRAL Financials: Income Statement, Balance Sheet & Cash Flow
Grail Inc (GRAL) financials indicate low profitability with a negative operating margin of -1743.0% and a net loss of -$2.0 billion in fiscal year 2024, despite a 34.9% revenue growth to $125.6 million. The company demonstrates strong liquidity and low leverage, yet its earnings quality is low, driven by accounting accruals rather than cash generation. The estimated cash runway based on current burn rate is approximately 4 months.
Samsung and GRAIL Announce Strategic Collaboration To Bring GRAIL’s Galleri® Multi-Cancer Early Detection Test to Asia - Samsung Newsroom Global Media Library
Samsung C&T and Samsung Electronics have announced a strategic collaboration with GRAIL, Inc. to introduce GRAIL’s Galleri® multi-cancer early detection test to key Asian markets. As part of the collaboration, Samsung C&T and Samsung Electronics will invest $110 million into GRAIL at $70.05 per share. This partnership aims to enhance early cancer detection capabilities in Asia, utilizing GRAIL's technology.
GRAIL (NASDAQ:GRAL) President Joshua Ofman Sells 17,002 Shares
GRAIL President Joshua Ofman sold 17,002 shares of the company's stock for over $852,000 on March 2nd, reducing his stake by 3.75%. The company, which focuses on early cancer detection, reported better-than-expected quarterly EPS but remains unprofitable with a market cap of $2.06 billion. Analyst ratings are mixed with an average "Hold" rating and a price target of $90.17, although some firms have recently lowered their targets.
GRAIL (GRAL) CEO sells 37,504 shares in automatic tax sell-to-cover
GRAIL, Inc. CEO Robert P. Ragusa sold 37,504 shares through automatic "sell-to-cover" transactions to meet tax withholding obligations tied to equity award vesting. The transactions involved selling 35,787 shares at an average of $50.0853 and 1,717 shares at $51.8430. Following these sales, Ragusa directly holds 650,525 shares of GRAIL common stock.
GRAL: Affiliate to sell 36,923 vested RSU shares (Form 144)
A Form 144 SEC filing indicates that an affiliate of GRAIL, Inc. (GRAL) intends to sell 36,923 shares of common stock. These shares were acquired on February 28, 2026, upon the vesting of restricted stock units. The filing also notes a previous sale of 13,000 shares by Joshua J. Ofman on December 3, 2025, for $1,300,000.
Aaron Freidin to sell 23,076 GRAL shares under Rule 144 (NASDAQ: GRAL)
Aaron Freidin has filed a Form 144 to sell 23,076 shares of GRAL (GRAIL, Inc.) common stock. These shares were acquired on February 28, 2026, upon the vesting of restricted stock units. The filing also indicates a previous sale of 25,000 shares by Freidin on December 3, 2025.
